Badalona

• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha … Ended recruitment
  2023-506588-32-00 5 2020-06-12 Relapsed and Lenalidomide-Refractory Multiple Myeloma
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed … Ended recruitment
  2023-510537-28-00 5 2020-05-15 Multiple Myeloma
• Utility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutations Ended recruitment
  2024-511317-38-00 4 2020-05-04 ALK+ non-small cell lung cancer
• Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age Ended recruitment
  2022-501974-21-00 5 2020-04-01 Prevention of oral persistent infection caused by any of the human pap
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9) Ended recruitment
  2023-507060-39-00 3 2020-03-04 Multiple Myeloma
• A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subj … Ended recruitment
  2023-503468-17-00 3 2020-03-02 Multiple myeloma
• A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended recruitment
  2023-506783-14-00 5 2020-02-24 Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201 Ended recruitment
  2023-508830-33-00 4 2019-12-13 Patients diagnosed with advanced or metastatic cancer treated with Tra
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Stu … Ended recruitment
  2023-505321-14-00 10 2019-09-06 Warm Autoimmune Hemolytic Anemia
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel … Ended recruitment
  2023-505219-19-00 9 2019-09-03 Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM
• Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, … Ended recruitment
  2024-516847-23-00 4 2019-08-27 ER-positive and HER2-negative metastatic or locally advanced breast ca
• A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors Ended recruitment
  2023-509605-77-00 1 2019-06-27 Advanced solid tumours
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer
• A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specifi … Ended recruitment
  2024-511798-31-00 7 2019-05-31 KRAS p.G12C Mutant Advanced Solid Tumors
• A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilep … Ended recruitment
  2023-508681-15-00 4 2019-05-28 Adult focal (partial onset) epilepsy
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre … Ended recruitment
  2023-509349-11-00 5 2019-03-22 Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
• A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended recruitment
  2024-510985-17-00 4 2019-03-14 First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia

Showing 553–576 of 775 trials